مقالات به زبان انگلیسی

پرینت

Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy

نوشته شده توسط businesswire در .

December 22, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the first patient has been treated in a Phase 2 clinical trial of ACE-083, the Company’s locally acting muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).